Cover Image
市場調查報告書

Glimepiride的中國市場

Investigation Report on China Glimepiride Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 334099
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Glimepiride的中國市場 Investigation Report on China Glimepiride Market, 2010-2019
出版日期: 2015年07月02日 內容資訊: 英文 30 Pages
簡介

中國的Glimepiride銷售額從2005年到2014年以30.7%的年複合成長率擴大,到2014年達成了2億2400萬人民幣的規模。

本報告提供中國的Glimepiride市場相關調查,提供您Glimepiride的功用·效果,中國市場上的專利及核准狀況,銷售額·銷售量的變化與預測,價格趨勢,並彙整主要製造商與市場佔有率,競爭環境及其展望,主要製造商簡介等資料。

第1章 Glimepiride的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國的Glimepiride的市場簡介

  • 專利情形
  • 主要製藥公司
  • 市場規模

第3章 中國的Glimepiride銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國的Glimepiride的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國的Glimepiride劑型的相關調查

  • 各劑型的市場佔有率:以銷售額為準
  • 各劑型的市場佔有率:以銷售量為準

第6章 中國的醫院的Glimepiride的標準價格

  • Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd (商品名:Amaryl)
  • Aventis(Italy)
  • Wanbang Biopharmaceuticals
  • Zhongnuo Pharma
  • Tianan Pharmaceutical
  • Guangzhou Hairui Pharmaceutical Co., Ltd
  • Sichuan Pudu Pharmaceutical Plant

第7章 中國市場中Glimepiride的主要製藥公司

  • Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd
  • Aventis(Italy)
  • Wanbang Biopharmaceuticals
  • Zhongnuo Pharma
  • Tianan Pharmaceutical
  • Guangzhou Hairui Pharmaceutical Co., Ltd

第8章 中國的Glimepiride的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1507260

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

Sulfonylurea has developed into an important part of oral antidiabetic drug ever since its first generation came into the market in 1956. As an insulin secretagogue, sulfonylurea directly acts on sulfonylurea receptor on the cell membrane of pancreatic beta cells, stimulates the release of insulin and enhances postprandial elevated blood sugar's excitation upon insulin release. Currently, glimepiride is the best-selling product of sulfonylurea in the Chinese market.

First developed and marketed by Dr. Willmar Schwabe Gmbh Co. KG under the trade name of Amaryl in 1995, glimepiride has been approved by FDA as an oral drug that can be used alone or together with insulin. Ever since Aventis introduced glimepiride into China under the trade name of Amaryl in 2001, about 30 enterprises have got the approval to produce it.

Glimepiride can also sensitize beta cells to insulin, ameliorate insulin resistance and it works best outside prancreas. By increasing glucose transporter (GLUT1 and GLUT2), glimepiride can recover glucose absorption so as to maintain the normal level of blood sugar. Characterized by small dose, few side effects, wide application and low rate of hypoglycemia, glimepiride can treat insulin secretion deficiency, recover glucose absorption and relieve hyperinsulinemia.

According to CRI's market survey, in 2014, Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd took up a market share of about 86% for sales value and Sanofi occupied nearly 90% of the glimepiride market in China if Aventis (Italy)'s 3.8% is counted too. The rest market share were occupied by such companies like Wanbang Biopharmaceuticals, Zhongnuo Pharma and Tianan Pharmaceutical. The sales value of glimepiride in sample hospitals was CNY 224 million in 2014 and CAGR reached 30.7% during the period of 2005-2014.

The market size of glimepiride is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:

  • market size of glimepiride in China
  • major manufacturers of glimepiride for Chinese market and their market share
  • retail price of glimepiride in Chinese market
  • market outlook of glimepiride in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Glimepiride

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Glimepiride in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Glimepiride in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Glimepiride in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Glimepiride in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Glimepiride in Chinese Hospitals in 2014

  • 6.1. Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd (Trade Name: Amaryl)
  • 6.2. Aventis(Italy)
  • 6.3. Wanbang Biopharmaceuticals
  • 6.4. Zhongnuo Pharma
  • 6.5. Tianan Pharmaceutical
  • 6.6. Guangzhou Hairui Pharmaceutical Co., Ltd
  • 6.7. Sichuan Pudu Pharmaceutical Plant

7. Major Manufacturers of Glimepiride in Chinese Market, 2010-2014

  • 7.1. Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd
  • 7.2. Aventis(Italy)
  • 7.3. Wanbang Biopharmaceuticals
  • 7.4. Zhongnuo Pharma
  • 7.5. Tianan Pharmaceutical
  • 7.6. Guangzhou Hairui Pharmaceutical Co., Ltd

8. Market Outlook of Glimepiride in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Registration Information of Glimepiride in China
  • Chart Approval Status of Glimepiride in China
  • Chart Sales Status of Glimepiride in China, 2010-2014
  • Chart Sales Value of Glimepiride in China, 2010-2014
  • Chart Sales Value of Glimepiride by Regions in China, 2010-2014
  • Chart Sales Value of Glimepiride Tablets in China, 2010-2014
  • Chart Sales Value of Glimepiride Capsules in China, 2010-2014
  • Chart Market Share of Major Manufacturers of Glimepiride for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Glimepiride Made by Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd, 2010-2014
  • Chart Sales Value and Market Share of Glimepiride Made by Aventis (Italy), 2010-2014
  • Chart Sales Value and Market Share of Glimepiride Made by Wanbang Biopharmaceuticals, 2010-2014
  • Chart Sales Value and Market Share of Glimepiride Made by Zhongnuo Pharma, 2010-2014
  • Chart Price of Glimepiride Made by Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd in Some Chinese Cities, 2010-2014
  • Chart Price of Glimepiride Made by Aventis (Italy) in Some Chinese Cities, 2010-2014
  • Chart Price of Glimepiride Made by Wanbang Biopharmaceuticals in Some Chinese Cities, 2010-2014
  • Chart Price of Glimepiride Made by Zhongnuo Pharma in Some Chinese Cities, 2010-2014
Back to Top